Company / Free Cash Flow
Lineage Cell Therapeutics, Inc. Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$19.4M
FY2025
5-year range
-$29.2M / -$19.4M
FY2021-FY2025
Trend
+17.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Free Cash Flow has fluctuated over the past 10 years, ranging from -$46M in FY2017 to -$19M in FY2025.
Based on SEC 10-K filings.
-$19M in FY2025.
Improved from -$29M to -$19M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, free cash flow increased 17.8% year-over-year.
- Lowest free cash flow in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score -3.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$19.4M | +17.8% |
| FY2024 | -$23.7M | +19.1% |
| FY2023 | -$29.2M | -22.3% |
| FY2022 | -$23.9M | -20.6% |
| FY2021 | -$19.8M | +38.8% |
| FY2020 | -$32.4M | -3.0% |
| FY2019 | -$31.4M | +1.3% |
| FY2018 | -$31.8M | +30.5% |
| FY2017 | -$45.8M | -16.4% |
| FY2016 | -$39.3M | -23.8% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026